Remedium Bio raises $10M Series A to develop adjustable gene therapies

What's the deal? Remedium Bio has announced the initial close of a planned $10 million Series A to develop durable, adjustable gene therapies for chronic disease. Lifespan Vision VenturesDealroom has a profile for this one. Try Dealroom → led the round, with Eli Lilly and CompanyDealroom has a profile for this one. Try Dealroom → and HKX Capital participating. Harry Robb of Lifespan Vision Ventures has joined Remedium's board.

Why it matters: The Boston biotech's Prometheus platform is designed to turn adipocytes (fat cells) into long-term producers of therapeutic proteins, delivered via a minimally invasive subcutaneous injection. Rather than repeatedly administering a protein, Remedium aims to provide the genetic instructions for a patient's own cells to manufacture it, potentially for years, while retaining the ability to adjust expression after treatment.

What's next? The financing will support Remedium's lead programmes and preparations for first-in-human studies. The company expects to complete the round with a further group of investors before final close.

The signal: Gene therapy is increasingly blurring into drug delivery rather than simple gene replacement. Remedium's bet is that long-lived genetic programming need not mean surrendering control of the dose.

Read more: Longevity.Technology

Image credit: Generated with Gemini